CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( <i>NRG1</i> ) Fusions

20252 citationsJournal Articlehybrid Open Access

Authors

These results support the antitumor activity and safety of seribantumab in patients with advanced solid tumors harboring <i>NRG1</i> fusions.

Good health and well-being

Published in: JCO Precision Oncology

Volume 9, Issue 9, pp. e2500221-e2500221

Field-Weighted Citation Impact: 2.09